Prime Medicine (PRME) Income towards Parent Company (2021 - 2026)

Prime Medicine (PRME) has 6 years of Income towards Parent Company data on file, last reported at -$228.7 million in Q1 2026.

• Quarterly Income towards Parent Company fell 340.77% year-over-year to -$228.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$453.2 million (down 124.36% YoY) and the FY2025 annual result came in at -$204.2 million, down 4.25% from the prior year.
• Income towards Parent Company eased to -$228.7 million in Q1 2026, from -$47.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$23.8 million in Q1 2022 to a low of -$228.7 million in Q1 2026.
• A 5-year average of -$60.1 million and a median of -$47.5 million in 2025 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company jumped 37.56% — and 2026, when it tumbled 340.77%.
• Tracing PRME's Income towards Parent Company over 5 years: stood at -$39.3 million in 2022, then slumped by 67.1% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then dropped by 12.42% to -$47.5 million in 2025, then slumped by 381.22% to -$228.7 million in 2026.
• The last three Income towards Parent Company figures came in at -$228.7 million (Q1 2026), -$47.5 million (Q4 2025), and -$124.4 million (Q3 2025), per Business Quant data.